Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Pritchard-Jones, Kathy; Bergeron, Christophe; de Camargo, Beatriz; van den Heuvel-Eibrink, Marry M; Acha, Tomas; Godzinski, Jan; Oldenburger, Foppe; Boccon-Gibod, Liliane; Leuschner, Ivo; Vujanic, Gordan; Sandstedt, Bengt; de Kraker, Jan; van Tinteren, Harm; Graf, Norbert; Ansari Djaberi, Marc Georges; SIOP Renal Tumours Study Group

doi:10.1016/S0140-6736(14)62395-3

Scientific article

English

Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

ContributorsPritchard-Jones, Kathy; Bergeron, Christophe; de Camargo, Beatriz; van den Heuvel-Eibrink, Marry M; Acha, Tomas; Godzinski, Jan; Oldenburger, Foppe; Boccon-Gibod, Liliane; Leuschner, Ivo; Vujanic, Gordan; Sandstedt, Bengt; de Kraker, Jan; van Tinteren, Harm; Graf, Norbert; Ansari Djaberi, Marc Georges; SIOP Renal Tumours Study Group

Published inThe Lancet, vol. 386, no. 9999, p. 1156-1164

Publication date2015

Abstract

Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III, histological intermediate-risk Wilms' tumour when a newly defined high-risk blastemal subtype was excluded from randomisation.

Keywords

Adolescent
Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
Chemotherapy, Adjuvant/adverse effects/methods
Child
Child, Preschool
Dactinomycin/administration & dosage/adverse effects
Doxorubicin/administration & dosage/adverse effects
Female
Humans
Infant
Kaplan-Meier Estimate
Kidney Neoplasms/drug therapy/pathology/surgery
Male
Neoadjuvant Therapy/adverse effects/methods
Neoplasm Staging
Nephrectomy
Treatment Outcome
Vincristine/administration & dosage/adverse effects
Wilms Tumor/drug therapy/pathology/surgery

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Research groups

Oncologie et hématologie pédiatrique (907)

Citation (ISO format)

PRITCHARD-JONES, Kathy et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms” tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. In: The Lancet, 2015, vol. 386, n° 9999, p. 1156–1164. doi: 10.1016/S0140-6736(14)62395-3

Article (Published version)

CC0

Identifiers

PID : unige:97169
DOI : 10.1016/S0140-6736(14)62395-3
PMID : 26164096

ISSN of the journal0140-6736

519views

213downloads

Creation09/29/2017 12:23:00 PM

First validation09/29/2017 12:23:00 PM

Update time03/15/2023 2:04:40 AM

Status update03/15/2023 2:04:39 AM

Last indexation10/31/2024 7:55:11 AM

Archive ouverte UNIGE

Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Technical informations